CO5690556A2 - Metodos y composiciones para la inhibicion de selectina - Google Patents

Metodos y composiciones para la inhibicion de selectina

Info

Publication number
CO5690556A2
CO5690556A2 CO06045580A CO06045580A CO5690556A2 CO 5690556 A2 CO5690556 A2 CO 5690556A2 CO 06045580 A CO06045580 A CO 06045580A CO 06045580 A CO06045580 A CO 06045580A CO 5690556 A2 CO5690556 A2 CO 5690556A2
Authority
CO
Colombia
Prior art keywords
aryl
heterocycle
arylalkyl
alkyl
hydrogen
Prior art date
Application number
CO06045580A
Other languages
English (en)
Inventor
Neelu Kaila
Silvano L Debernardo
Kristin M Janz
Raymond T Camphausen
Patricia W Bedard
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5690556A2 publication Critical patent/CO5690556A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

1.- Un compuesto caracterizado porque tiene la Fórmula I: o una sal farmacéuticamente aceptable del mismo;donde:L es CO2H, un éster del mismo o un mimético de ácido farmacéuticamente aceptable;Y es O, (CR3R4)p ó NR5;p es 1 a 3;X es hidrógeno, OH, OR3, Oalquilo C1-6, OC(=O) arilo, OC(=O) alquilo C1-6, OC(=O)O alquilo C1-6 ó NR3R3AND#39;cada R1, R2, R3, R3AND#39, y R4 es independientemente hidrógeno, alquilo C1-6, perhaloalquilo C1-6, Oalquilo C1-6, Operhaloalquilo C1-6, halógeno, tioalquilo, CN, OH, SH, (CH2)nOSO3H, (CH2)nSO3H, (CH2)nCO2R6, OSO3R6, SO2R6, SO3R6, PO3R6R7, (CH2)nSO2NR8R9, (CH2)nC(=O)NR8R9, NR8R9, C(=O)R12, arilo, heterociclo, C(=O) arilo, C(=O) heterociclo, OC(=O) arilo, OC(=O) heterociclo, Oarilo, Oheterociclo, arilalquilo, C(=O), arilalquilo OC(=O) arilalquilo, Oarilalquilo, alquenilo, alquinilo o NHCOR8, donde cualquiera de alquilo, Oalquilo, arilo, heterociclo, C(=O)arilo, C(=O) heterociclo, O-C(=O) arilo, O-C(=O) heterociclo, O-arilo, O-heterociclo, arilalquilo, C(=O)arilalquilo, C(=O)arilalquilo, O-arilalquilo, alquenilo o alquinilo pueden sustituirse opcionalmente con hasta tres sustitutos iguales o diferentes seleccionados de halógeno, alquilo C1-6, Oalquilo C1-6 y CN;cada R6 y R7 es independientemente seleccionado del grupo que comprende hidrógeno y alquilo C1-6 opcionalmente sustituido con hasta tres sustitutos iguales o diferentes seleccionados de OH, CF3, SH y halógeno;cada R5, R8 y R9 se selecciona independientemente del grupo que comprende hidrógeno, alquilo C1-6, haloalquilo C1-6, tioalquilo, OH, (CH2)IOSO3H, (CH2)ISO3R10, (CH2)nCO2R10, SO3R10, PO3R10R11, (CH2)nSO2(CH2)nNR10R11, (CH2)nCONR10R11, COR10, arilo, heterociclo, C(=O) arilo, C(=O) heterociclo, O-C(=O)arilo, O-C(=O)heterociclo, Oarilo, Oheterociclo, arilalquilo, C(=O)arilalquilo, OC(=O) arilalquilo, Oarilalquilo, alquenilo o alquinilo, donde cada uno de alquilo, arilo, heterociclo, C(=O) arilo, C(=O) heterociclo, OC(=O) arilo, OC(=O) heterociclo, Oarilo, Oheterociclo, arilalquilo, C(=O) arilalquilo, OC(=O) arilalquilo, Oarilalquilo, ...
CO06045580A 2003-11-10 2006-05-12 Metodos y composiciones para la inhibicion de selectina CO5690556A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51895003P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
CO5690556A2 true CO5690556A2 (es) 2006-10-31

Family

ID=34590327

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06045580A CO5690556A2 (es) 2003-11-10 2006-05-12 Metodos y composiciones para la inhibicion de selectina

Country Status (21)

Country Link
US (2) US7465799B2 (es)
EP (1) EP1682511A2 (es)
JP (1) JP2007510742A (es)
KR (1) KR20060108666A (es)
CN (1) CN1902179A (es)
AR (1) AR046704A1 (es)
AU (1) AU2004288800A1 (es)
BR (1) BRPI0416357A (es)
CA (1) CA2544693A1 (es)
CO (1) CO5690556A2 (es)
CR (1) CR8384A (es)
EC (1) ECSP066558A (es)
GT (1) GT200400232A (es)
IL (1) IL175389A0 (es)
NO (1) NO20062348L (es)
PA (1) PA8617101A1 (es)
PE (1) PE20050579A1 (es)
RU (1) RU2006120450A (es)
TW (1) TW200526583A (es)
WO (1) WO2005047257A2 (es)
ZA (1) ZA200603683B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465798B2 (en) * 2003-11-10 2008-12-16 Wyeth Methods and compositions for selectin inhibition
WO2007022946A1 (de) * 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US20080125454A1 (en) * 2006-10-05 2008-05-29 Wyeth Methods and Compositions for Treatment of Scleritis and Related Disorders
CN101646652A (zh) * 2007-03-30 2010-02-10 惠氏公司 用于选择素抑制的喹啉衍生物和包含喹啉衍生物的医药组合物
WO2008121805A1 (en) 2007-03-30 2008-10-09 Wyeth Methods and compositions for selectin inhibition
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
AU1804299A (en) * 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU2002345796A1 (en) 2001-06-26 2003-03-03 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
CA2453060C (en) * 2001-07-06 2011-02-08 Nippon Kayaku Kabushiki Kaisha Dye-sensitized photoelectric conversion device

Also Published As

Publication number Publication date
NO20062348L (no) 2006-08-01
CN1902179A (zh) 2007-01-24
WO2005047257A2 (en) 2005-05-26
JP2007510742A (ja) 2007-04-26
TW200526583A (en) 2005-08-16
AU2004288800A1 (en) 2005-05-26
GT200400232A (es) 2005-09-14
PA8617101A1 (es) 2006-09-22
CA2544693A1 (en) 2005-05-26
EP1682511A2 (en) 2006-07-26
ECSP066558A (es) 2006-10-17
ZA200603683B (en) 2008-05-28
US7465799B2 (en) 2008-12-16
IL175389A0 (en) 2006-09-05
WO2005047257A3 (en) 2005-07-07
PE20050579A1 (es) 2005-09-08
KR20060108666A (ko) 2006-10-18
AR046704A1 (es) 2005-12-21
US20050101568A1 (en) 2005-05-12
RU2006120450A (ru) 2007-12-27
CR8384A (es) 2006-12-07
BRPI0416357A (pt) 2007-05-08
US20090076077A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
CO5690556A2 (es) Metodos y composiciones para la inhibicion de selectina
ES2528451T3 (es) Inhibidores de esfingosina cinasa
AR068912A1 (es) Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
AR080326A1 (es) Tienipirimidinas que contienen cicloalquilo para composiciones farmaceuticas
CO5611131A2 (es) Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa
CO5690557A2 (es) Metodos y composiciones para inhibicion de selectina
AR061974A1 (es) Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
AR073254A1 (es) Analogos de piridona y piridazona como moduladores de gpr119
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
AR054195A1 (es) Derivados de indol como inhibidores de la fosfolipasa a2 citosolica y composicion farmaceutica que los contiene
CO5640090A2 (es) Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion
AR066448A1 (es) Inhibidores macrociclicos de la replicacion del virus de hepatitis c, composicion farmaceutica, metodos de obtencion del compuesto y compuestos intermediarios
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
AR058077A1 (es) Derivados de acidos fenoxiaceticos
CO5640041A2 (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
AR064729A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR082619A1 (es) Inhibidores del virus de la hepatitis c
BR112015015275A8 (pt) composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso
AR057980A1 (es) Derivados de la 1- amino-ftalazina sustituida, su preparacion y composicion farmaceutica
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
AR047606A1 (es) 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos

Legal Events

Date Code Title Description
FA Application withdrawn